JP2018512585A - 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ - Google Patents

癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ Download PDF

Info

Publication number
JP2018512585A
JP2018512585A JP2017548041A JP2017548041A JP2018512585A JP 2018512585 A JP2018512585 A JP 2018512585A JP 2017548041 A JP2017548041 A JP 2017548041A JP 2017548041 A JP2017548041 A JP 2017548041A JP 2018512585 A JP2018512585 A JP 2018512585A
Authority
JP
Japan
Prior art keywords
ecgf
cancer
sample
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017548041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512585A5 (enExample
Inventor
カサノバ、オリオル カサノバ
カサノバ、オリオル カサノバ
バレリオ、ガブリエラ ヒメネス
バレリオ、ガブリエラ ヒメネス
デ オルサ、マリア オチョア
デ オルサ、マリア オチョア
ペレス、バレンティ ナバロ
ペレス、バレンティ ナバロ
バサニ、ニクラス
ベルダグエル、エレナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Publication of JP2018512585A publication Critical patent/JP2018512585A/ja
Publication of JP2018512585A5 publication Critical patent/JP2018512585A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017548041A 2015-03-11 2016-03-10 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ Pending JP2018512585A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382109.5 2015-03-11
EP15382109.5A EP3067698A1 (en) 2015-03-11 2015-03-11 Pd-ecgf as biomarker of cancer
PCT/EP2016/055143 WO2016142471A1 (en) 2015-03-11 2016-03-10 Pd-ecgf as biomarker of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144291A Division JP2020201278A (ja) 2015-03-11 2020-08-28 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ

Publications (2)

Publication Number Publication Date
JP2018512585A true JP2018512585A (ja) 2018-05-17
JP2018512585A5 JP2018512585A5 (enExample) 2019-04-04

Family

ID=52737037

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017548041A Pending JP2018512585A (ja) 2015-03-11 2016-03-10 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ
JP2020144291A Pending JP2020201278A (ja) 2015-03-11 2020-08-28 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ
JP2022113650A Active JP7453284B2 (ja) 2015-03-11 2022-07-15 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020144291A Pending JP2020201278A (ja) 2015-03-11 2020-08-28 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ
JP2022113650A Active JP7453284B2 (ja) 2015-03-11 2022-07-15 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ

Country Status (11)

Country Link
US (2) US11802874B2 (enExample)
EP (2) EP3067698A1 (enExample)
JP (3) JP2018512585A (enExample)
KR (1) KR102513020B1 (enExample)
CN (1) CN107667292B (enExample)
AU (1) AU2016231086B8 (enExample)
ES (1) ES2896056T3 (enExample)
HK (1) HK1250582A1 (enExample)
MX (1) MX384046B (enExample)
PL (1) PL3268744T3 (enExample)
WO (1) WO2016142471A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510835A (ja) * 2018-01-15 2021-04-30 フンダシオン インスティテュート デ インベスティガシオン サニタリア デ サンティアゴ デ コンポステーラ （フィディス） Ｔａｓ１ｒ３タンパク質を発現する腫瘍に関する治療目的、診断目的及び／又は予後診断目的のマーカーとしてのｔａｓ１ｒ３タンパク質の使用
US12624695B2 (en) 2024-09-19 2026-05-12 Mahle International Gmbh Oil separator for compressor and compressor with oil separator

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08183800A (ja) * 1994-12-28 1996-07-16 Taiho Yakuhin Kogyo Kk モノクローナル抗体
JP2005073698A (ja) * 2003-08-28 2005-03-24 F Hoffmann La Roche Ag 結腸直腸癌のＴＰとＤＰＤｍＲＮＡ発現レベルの比率と５−ＦＵ治療患者における無病生存率の相関
CN101993919A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175980A1 (en) 2002-04-09 2005-08-11 Government Of The United States Of America, Repres By The Secretary, Dept. Of Health And Human Serv. Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
WO2007115376A1 (en) 2006-04-11 2007-10-18 The University Of Western Australia Anti-angiogenic agents and methods of their use
US8642349B1 (en) * 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
CA2751888C (en) * 2009-02-11 2022-06-14 Caris Mpi, Inc. Molecular profiling of tumors
US20120282631A1 (en) * 2009-03-20 2012-11-08 The Hong Kong Polytechnic University Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers
US20100317029A1 (en) * 2009-06-15 2010-12-16 Lih-Chyang Chen Nasopharyngeal cancer malingancy biomarker and method thereof
US8110675B2 (en) 2009-06-15 2012-02-07 Chang Gung University TP expression-inhibiting compound and siRNA sequence thereof
US9128101B2 (en) * 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2012129448A1 (en) 2011-03-23 2012-09-27 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
AU2013207778B2 (en) * 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08183800A (ja) * 1994-12-28 1996-07-16 Taiho Yakuhin Kogyo Kk モノクローナル抗体
JP2005073698A (ja) * 2003-08-28 2005-03-24 F Hoffmann La Roche Ag 結腸直腸癌のＴＰとＤＰＤｍＲＮＡ発現レベルの比率と５−ＦＵ治療患者における無病生存率の相関
CN101993919A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHRISTINE BROSTJAN; ET AL: "MONITORING OF CIRCULATING ANGIOGENIC FACTORS IN DENDRITIC CELL-BASED CANCER IMMUNOTHERAPY", CANCER, vol. VOL:98, NR:10, JPN5018001178, 29 September 2003 (2003-09-29), US, pages 2291 - 2301, ISSN: 0004407226 *
FUJIMOTO J; SAKAGUCHI H; HIROSE R; ICHIGO S; TAMAYA T: "EXPRESSION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (PD-ECGF) AND ITS MRNA IN UTERINE CERV", BRITISH JOURNAL OF CANCER, vol. VOL:79, NR:7/8, JPN5018001179, March 1999 (1999-03-01), GB, pages 1249 - 1254, ISSN: 0004407228 *
JIRO FUJIMOTO: "The Value of Platelet-derived Endothelial Cell Growth Factor as a Novel Predictor of Advancement of", CANCER RESEARCH, vol. 60, JPN6019045160, 1 July 2000 (2000-07-01), pages 3662 - 3665, ISSN: 0004407230 *
KENJI JIN-NO: "Circulating Platelet-Derived Endothelial Cell Growth Factor Increses in Hepatocellular Carcinoma Pat", CANCER, vol. Volume 82/Number 7, JPN6019045159, 1 April 1998 (1998-04-01), pages 1260 - 1266, ISSN: 0004407229 *
MORITA T; MATSUZAKI A; TOKUE A: "QUANTITATIVE ANALYSIS OF THYMIDINE PHOSPHORYLASE AND DIHYDROPYRIMIDINE DEHYDROGENASE IN RENAL CELL C", ONCOLOGY : INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, vol. VOL:65, NR:2, JPN5018001174, August 2003 (2003-08-01), CH, pages 125 - 131, ISSN: 0004407227 *
TAKAYAMA T; ET AL: "HIGH LEVELS OF THYMIDINE PHOSPHORYLASE AS AN INDEPENDENT PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA", JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. VOL:36, NR:9, JPN5018001173, 26 July 2006 (2006-07-26), pages 564 - 569, ISSN: 0004407224 *
TSUJI T; ET AL: "PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR IN CO", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY (EJSO), vol. VOL:30, NR:3, JPN5018001177, April 2004 (2004-04-01), pages 296 - 302, ISSN: 0004407225 *
YUTAKA YAMAMOTO: "Prediction of the effect of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine ph", ONCOLOGY REPORTS, vol. 3, JPN6019045161, 1996, pages 863 - 865, ISSN: 0004157778 *

Also Published As

Publication number Publication date
AU2016231086B2 (en) 2021-08-12
US20180052164A1 (en) 2018-02-22
MX2017011467A (es) 2018-01-23
US12298307B2 (en) 2025-05-13
PL3268744T3 (pl) 2021-12-27
HK1250582A1 (zh) 2019-01-04
KR102513020B1 (ko) 2023-03-21
EP3268744A1 (en) 2018-01-17
JP7453284B2 (ja) 2024-03-19
CN107667292B (zh) 2020-06-19
EP3268744B1 (en) 2021-08-11
EP3067698A1 (en) 2016-09-14
CN107667292A (zh) 2018-02-06
JP2022153482A (ja) 2022-10-12
WO2016142471A1 (en) 2016-09-15
US20240069029A1 (en) 2024-02-29
AU2016231086A1 (en) 2017-09-28
JP2020201278A (ja) 2020-12-17
AU2016231086B8 (en) 2022-02-03
US11802874B2 (en) 2023-10-31
CA2978653A1 (en) 2016-09-15
MX384046B (es) 2025-03-14
KR20170123638A (ko) 2017-11-08
ES2896056T3 (es) 2022-02-23
AU2016231086A8 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
Henry et al. Cancer biomarkers
BR112012001469B1 (pt) Método diagnóstico in vitro para diagnose de câncer endometrial
US20140315732A1 (en) Cancer diagnosis and treatment
US12298307B2 (en) PD-ECGF as biomarker of cancer
KR102561377B1 (ko) 마커 분자를 기반으로 화학요법으로 치료되어야 하는 개체를 식별하는 방법 및 관련 용도
Kim et al. Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy
TWI512294B (zh) 偵測致死系統之方法與組合物及其用途
JP2003504073A (ja) Ｂａｇ発現のレベルを測定することによる、癌患者の予後を決定するための方法
WO2016201555A1 (en) Methods and compositions for the diagnosis of a thyroid condition
CA2978653C (en) Pd-ecgf as biomarker of cancer
JP5145549B2 (ja) 腫瘍マーカー
KR102164525B1 (ko) Gdf 15를 포함하는 갑상선 암 진단 또는 갑상선 암 예후 예측용 바이오마커 조성물
EP2957913B1 (en) Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
TWI391660B (zh) 偵測致死細胞的方法與材料及其應用
EP2269073B1 (en) A method of assessing cancer status in a breast cancer patient
EP3052938B1 (en) Methods and products for the diagnosis and prognosis of ovarian tumor malignancy
WO2010060032A1 (en) Method for determining progression of ductal carcinoma in situ to invasive breast cancer
Class et al. Patent application title: Methods and Compositions for the Diagnosis of a Thyroid Condition
HK1243168A1 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200828

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200923

C12 Written invitation by the commissioner to file intermediate amendments

Free format text: JAPANESE INTERMEDIATE CODE: C12

Effective date: 20200923

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201127

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201211

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201215

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210112

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210803

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210831

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210831